Amrutanjan Health Care Limited Receives Order Regarding Input Tax Credit
Amrutanjan Health Care Limited announced today, March 18, 2026, that it received an order from the Additional Commissioner of Central Excise & Customs (Appeals-II) under the CGST/IGST Act, 2017. The order, dated March 17, 2026, relates to a review of input tax credit and questioning its eligibility for the years 2020-21 to 2021-22.The appellate authority's order mandates a reversal of input tax credit due to a GSTR2A mismatch. The total tax demand amount is Rs. 24,28,910, inclusive of applicable interest and penalty.
According to the company, it availed input tax credit after fulfilling all stipulated conditions according to the GST law. Amrutanjan Health Care Limited intends to file an appeal against the order, believing the case holds merit. The company stated that the order is not expected to have significant financial implications.
| Particulars | Information/ Remarks |
|---|---|
| NameoftheAuthority | Additional Commissioner of Central Excise & customs (Appeals-II) |
| Nature and details of the action(s) taken, initiated or order(s) passed; | Order passed under section 73 & 74 of CGST Act 2017. |
| Date of order, including any ad-interim or interim orders, or any other communication from the authority; | 17 th March 2026 |
| Details of the violation(s)/contravention(s) committed or alleged to be committed | First appellate authority passed an order for reversal of Input tax credit on account of GSTR2A mismatch and questioning the eligibility of input tax credit for the years 2020-21 to 2021-22. The tax demand amount is Rs.24,28,910 and applicable interest/penalty |
| Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible. | The Company availed Input tax credit after fulfilling all the conditions as per the provisions of GST law. Accordingly, based on merits of the case, the Company will be filing appeal against the Order. This Order does not have any major financial implications on the company |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.